title: Neurocrine Biosciences
id: 5249173
Neurocrine Biosciences Inc is an American biopharmaceutical company founded in The company is headquartered in San Diego California and led by CEO Kevin Gorman Neurocrine develops treatments for neurological and endocrine related diseases and disorders In the company s drug valbenazine Ingrezza was approved in the US to treat adults with tardive dyskinesia TD br The company is also developing treatments that are in various stages of clinical research for Parkinson s disease Tourette syndrome and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids br br br History br br Neurocrine was founded in San Diego California in The company s academic founders were Wylie Vale of the Salk Institute for Biological Studies and Lawrence Steinman of Stanford University The company was backed by Avalon Ventures among others br In the company collaborated with Belgium based Janssen Pharmaceutica N V to develop treatments for psychiatric disorders utilizing corticotropin releasing factor CRF antagonists a class of compounds to treat psychiatric neurological and gastrointestinal diseases including anxiety depression and irritable bowel syndrome The company underwent an IPO in May listing on the NASDAQ exchange under the symbol NBIX and raising million br In October Eli Lilly and Company agreed to pay Neurocrine million over five years to develop drugs for obesity and Alzheimer s disease based on its research of CRF binding protein ligand inhibitors br In July Neurocrine and GlaxoSmithKline entered into a worldwide research development and commercialization agreement including a collaborative research program for up to five years to identify and develop CRF R antagonist compounds The collaboration also included worldwide development and commercialization of NBI as well as potential backup candidates resulting from the research program Neurocrine received upfront fees and early milestone payments totaling million br In December Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug indiplon The deal paid Neurocrine million initially with a possible million more if the drug met regulatory and sales goals In May the FDA issued a non approvable letter for a modified release mg formulation of indiplon and an approvable letter with stipulations for mg and mg immediate release formulations As a result Pfizer terminated its agreement with Neurocrine Following a resubmission of the mg and mg formulations in December Neurocrine s new drug application was deemed approvable but the FDA requested additional studies The company discontinued development of the drug in the United States In Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan The deal paid Neurocrine million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan br Kevin Gorman replaced Gary Lyons as CEO of the company in January Lyons was CEO and president of the company since its founding and maintained a role on the company s board of directors br On June Neurocrine agreed to a deal with AbbVie Inc previously Abbott Laboratories worth up to million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix an oral gonadotropin releasing hormone GnRH antagonist to treat endometriosis and uterine fibroids The deal paid Neurocrine million up front br In April the FDA approved valbenazine for the treatment of TD At the time of approval it was the first and only drug approved for adults with TD Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome In October Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome br In February Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson s disease drug opicapone in North America with the Portugal based pharmaceutical company Bial As part of the agreement Neurocrine provided an upfront payment of million and agreed to fund development activities for FDA approval in the United States Bial is eligible to receive additional milestone payments of up to million and a percentage of net sales br In September AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain The submission was supported by two similar Phase clinical studies involving women In October AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA A final regulatory decision on the drug will come during the third quarter of The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development br br br Product pipeline br Elagolix gonadotropin releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids br Opicapone A once daily catechol O methyl transferase inhibitor in trials for Parkinson s disease br NBI Corticotropin releasing factor CRF receptor agonist br br br br br br External links br Official website br Business data for Neurocrine Biosciences Inc 